Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019958 | 0.89 | HTR1A (0.54) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL15227112 | 0.82 | KDM1A (0.46) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL5020019 | 0.81 | HTR6 (0.54) | HTR1ASLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL15236731 | 0.79 | HTR2C (0.53) | HTR1ASLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL5020041 | 0.78 | HTR6 (0.42) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL5020013 | 0.78 | CCNT1 (0.48) | SIGMAR1HTR2CHTR6HTR2ACCNT1 | |
| SCHEMBL17398223 | 0.76 | HTR6 (0.42) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL5020009 | 0.74 | HTR1A (0.51) | HTR1ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL31640013 | 0.73 | HTR6 (0.52) | SIGMAR1HTR2CPRMT5HTR6CCNT1 | |
| SCHEMBL4672600 | 0.72 | PRMT5 (0.64) | SLC6A2SLC6A3SIGMAR1HTR2CPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | HTR1A 702/4885SLC6A2 182/4885SLC6A4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.